Mind Cure Welcomes Award-Winning Journalist and Science Researcher Hamilton Morris to Advisory Board
This news release is not for distribution to U.S. newswire services for dissemination in the United States.
Vancouver, BC – October 6, 2020 – Mind Cure Health Inc. (CSE:MCUR) (“Mind Cure” or the “Corporation”), is pleased today to announce the addition of Hamilton Morris to the company's advisory board. Mr. Morris is a chemist, filmmaker, and science journalist. His research has allowed him to study psychoactive plants, fungi, and chemicals as well as the culture that surrounds them in more than thirty countries using an interdisciplinary approach that combines anthropology and chemistry.
In his role as advisor, Mr. Morris will bring his renowned scientific and anthropological approach to Mind Cure, and in so doing will support the team in advising on new product candidate opportunities and their merits. Mr. Morris has been an active member of the scientific community during the psychedelic renaissance and is well respected for both his novel and disciplined, science-first position in its advancement.
"The potential of psychedelics and new medicines to treat mental illness is significant," said Mr. Morris. "As a researcher and journalist, my work is always driven by science. I look forward to working with the team at Mind Cure as they research and discover new products to treat mental health."
Philip Tapley, Chairman, President, and CEO stated, "Hamilton is one of the most respected leaders in the industry. His research and journalistic work have helped bring attention to the opportunities available to improve the treatment of mental health through the use of new medicines and treatments. He will be another key piece of our advisory board as we move forward."
Mind Cure believes that a revolution is coming to the mental health space, and that innovation and investment will lead to a major disruption in how mental health is treated. With Hamilton, Mind Cure intends to further its investigation into new product candidates and treatments which are effective in treating mental health. These new product candidates range from nootropics to psychoactive products and psychedelic substances.
About Hamilton Morris
Hamilton Morris is a chemist, filmmaker, and science journalist. He is the director of the award-winning documentary series Hamilton's Pharmacopeia in which he explores the chemistry and traditions surrounding psychoactive drugs. His research has allowed him to study psychoactive plants, fungi, and chemicals as well as the culture that surrounds them in more than thirty countries using an interdisciplinary approach that combines anthropology and chemistry.
Hamilton attended the University of Chicago and The New School in New York City, where he studied anthropology and science. He frequently consults with media on the subject of psychoactive drugs and conducts pharmacological research at the University of the Sciences in Philadelphia.
About Mind Cure Health Inc.
Mind Cure is a mental health and wellness company with a mission to identify, develop and commercialize products that ease suffering, increase productivity, and enhance mental health. It is the therapeutic potential of nootropics, psychoactive products, and psychedelic substances to treat the profound distress of a world suffering from a mental health crisis that led to the formation of Mind Cure.
On behalf of the Board of Directors
Philip Tapley, Chairman, President, and CEO
Phone: +1 888 593-8995
Mind Cure Health Inc.
About this Press Release:
In Germany this press release is brought to you by Cannabisaktien.news – your German news platform for international cannabis stocks. For more information visit http://www.akt.ie/can-news
Certain statements in this news release may constitute "forward-looking information" within the meaning of applicable securities laws (also known as forward-looking statements). Forward-looking information involves known and unknown risks, uncertainties and other factors, and may cause actual results, performance or achievements or industry results, to be materially different from any future results, performance or achievements or industry results expressed or implied by such forward-looking information. Forward-looking information generally can be identified by the use of terms and phrases such as "anticipate", "believe", "could", "estimate", "expect", "feel", "intend", "may", "plan", "predict", "project", "subject to", "will", "would", and similar terms and phrases, including references to assumptions. Some of the specific forward-looking information in this news release includes, but is not limited to, statements with respect to: the timing of the resumption of trading of common shares on the CSE and the trading symbol of the Shares on the CSE.
Forward-looking information is based on a number of key expectations and assumptions made by Mind Cure, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and Mind Cure's business, and the extent and duration of such impact; no material change will occur before trading resumes on the CSE; no change to laws or regulations that negatively affect Mind Cure's business; there will be a demand for Mind Cure's products in the future; and Mind Cure will be able to operate its business as planned. Although the forward-looking information contained in this news release is based upon what Mind Cure believes to be reasonable assumptions, it cannot assure investors that actual results will be consistent with such information.
Forward-looking information is provided for the purpose of presenting information about management's current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: the impacts of the COVID-19 pandemic on the Canadian economy, Mind Cure's industry and Mind Cure's business, which may negatively impact, and may continue to negatively impact, Mind Cure and may materially adversely affect Mind Cure's investments, results of operations, financial condition and Mind Cure's ability to obtain additional equity or debt financing, and satisfy its financial obligations; the ability for Mind Cure's common shares to resume trading on the CSE; general economic conditions; future growth potential; common share prices; liquidity; tax risk; tax laws currently in effect remaining unchanged; ability to access capital markets; competition for mental health and wellness investments; environmental matters; and changes in legislation or regulations. Management believes that the expectations reflected in the forward-looking information contained herein are based upon reasonable assumptions and information currently available; however, management can give no assurance that actual results will be consistent with such forward-looking information. Additional information on the risk factors that could affect Mind Cure can be found under "Risk Factors" in the Prospectus which is available on SEDAR at www.sedar.com.
The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement. Forward-looking information reflects management's current beliefs and is based on information currently available to Mind Cure. The forward-looking information is stated as of the date of this news release and Mind Cure assumes no obligation to update or revise such information to reflect new events or circumstances, except as may be required by applicable law.
United States Advisory
The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), may be offered and sold outside the United States to eligible investors pursuant to Regulation S promulgated under the U.S. Securities Act, and may not be offered, sold, or resold in the United States or to, or for the account of or benefit of, a U.S. Person (as such term is defined in Regulation S under the United States Securities Act) unless the securities are registered under the U.S. Securities Act, or an exemption from the registration requirements of the U.S. Securities Act is available. Hedging transactions involving the securities must not be conducted unless in accordance with the U.S. Securities Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in the state in the United States in which such offer, solicitation or sale would be unlawful.
The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.
Aktuelle Pressemeldungen dieses Unternehmens direkt in Ihr Postfach:
Mitteilung übermittelt durch IRW-Press.com. Für den Inhalt ist der Aussender verantwortlich.
Kostenloser Abdruck mit Quellenangabe erlaubt.